Woscops study ppt to pdf

Prevention of Coronary Heart Disease with Pravastatin in ...

★ ★ ★ ★ ☆

Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with ...

Prevention of Coronary Heart Disease with Pravastatin in ...

West Of Scotland Coronary Prevention Study WOSCOPS

★ ★ ★ ☆ ☆

WOSCOPS Figure 1.2 Figure 1.1 Major primary prevention Evidence & Efficacy: Lipid-Modifying Therapy trials with statins West Of Scotland Coronary Prevention Study Reference Shepherd et al., for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with

West Of Scotland Coronary Prevention Study WOSCOPS

WOSCOPS - The Lancet

★ ★ ★ ★ ☆

The West of Scotland Coronary Prevention Group (Nov 16, p 1339)1 purports to have performed a subgroup analysis of placebo-treated men in the WOSCOPS population for the purpose of determining which risk factors are associated with the highest absolute risk of coronary heart disease (CHD). The investigators are to be commended for their efforts to provide this relevant information to practising ...

WOSCOPS - The Lancet

Long-Term Safety and Efficacy of Lowering Low-Density ...

★ ★ ★ ★ ★

Background—Extended follow-up of statin-based low-density lipoprotein cholesterol lowering trials improves the understanding of statin safety and efficacy. Examining cumulative cardiovascular events (total burden of disease) gives a better appreciation of the clinical value of statins. This article evaluates the long-term impact of therapy on mortality and cumulative morbidity in a high-risk ...

Long-Term Safety and Efficacy of Lowering Low-Density ...

WOSCOPS - The Lancet

★ ★ ★ ★ ★

To have analysed our data exclusively would have meant an impossibly wide confidence interval. An alternative approach to the study of the role of a large number of risk factors is to use more complex statistical modelling. A multivariate analysis of the WOSCOPS data will shortly appear.

WOSCOPS - The Lancet

Long-Term Safety and Efficacy of Lowering Low-Density ...

★ ★ ☆ ☆ ☆

Methods and Results—The West of Scotland Coronary Prevention Study was a primary prevention trial in 45- to 64-year-old men with high low-density lipoprotein cholesterol. A total of 6595 men were randomized to receive pravastatin 40 mg once daily or placebo for an average of 4.9 years.

Long-Term Safety and Efficacy of Lowering Low-Density ...

Landmark Clinical Trials - Lipid

★ ★ ☆ ☆ ☆

• Overview of Basic Study Design and Biostatistics • Prominent Landmark Clinical Trials: – Statin trials – LDL-C focused nonstatin trials – Mixed lipid modification focused nonstatin trials – Triglyceride/HDL-C focused nonstatin trials • Other Landmark Trials • Trials on the Horizon 3

Landmark Clinical Trials - Lipid

Introduction to pragmatic clinical trials - NIH Collaboratory

★ ★ ★ ★ ☆

The study is built around your normal health care operations. Will it take us more time?? Flexible study protocols minimize intrusion in your daily work flow. Will it help our patients?? The study’s explicit goal is to give you evidence that improves patient care & clinical …

Introduction to pragmatic clinical trials - NIH Collaboratory

atorvastatin ppt | Low Density Lipoprotein | Cholesterol

★ ★ ★ ☆ ☆

atorvastatin ppt - Download as Powerpoint Presentation (.ppt), PDF File (.pdf), Text File (.txt) or view presentation slides online. ... Framingham Heart Study MRFIT Screenees Study type Size of cohort Conclusions Epidemiologic 5127 (original) 1% in cholesterol = 2% in CHD risk Observational 361. Neaton JD. Arch Intern Med. 1992.4(suppl A):5A-10A.

atorvastatin ppt | Low Density Lipoprotein | Cholesterol

atorvastatin-ppt | Low Density Lipoprotein | Cholesterol

★ ★ ☆ ☆ ☆

atorvastatin-ppt - Free download as Powerpoint Presentation (.ppt), PDF File (.pdf), Text File (.txt) or view presentation slides online. gol statin

atorvastatin-ppt | Low Density Lipoprotein | Cholesterol

Long-Term Effects of Statin Treatment in Elderly People ...

★ ★ ★ ★ ★

The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a clinical trial in which 5804 men (n = 2804) and women (n = 3000) aged 70–82 years with a history of, or risk factors for, vascular disease were randomised to treatment with pravastatin (40 mg per day) or placebo.

Long-Term Effects of Statin Treatment in Elderly People ...

Intensive versus Moderate Lipid Lowering with Statins ...

★ ★ ★ ★ ☆

The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24 ...

Intensive versus Moderate Lipid Lowering with Statins ...

Statin Therapy: Review of Safety and Potential Side Effects

★ ★ ★ ★ ★

11/23/2015 · Other large trials investigating statin use in this population have also reported similar findings. 38, 40 It is worth noting that combination therapy with ezetimibe was associated with higher rates of myalgia in the SHARP study. 40 We would suggest continued statin therapy in patients with CKD with clinical monitoring for adverse effects ...

Statin Therapy: Review of Safety and Potential Side Effects

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year ...

★ ★ ★ ★ ★

UKPDS United Kingdom Prospective Diabetes Study WHO World Health Organization WOSCOPS West of Scotland Coronary Prevention Study v. vi Prevention of cardiovascular disease. Executive summary Cardiovascular disease is a major cause of disability and premature death throughout the

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year ...

Prevention of Cardiovascular Disease - who.int

★ ★ ★ ☆ ☆

SHARP Study of Heart and Renal Protection TNT Treating to New Targets UKPDS UK Prospective Diabetes Study USRDS United States Renal Data System VADT Veterans Affairs Diabetes Trial VA-HIT Veterans Affairs High-density lipoprotein Intervention Trial vs. Versus WOSCOPS West of Scotland Coronary Prevention Study Am J Kidney Dis. 2012;60(5):850-886 855

Prevention of Cardiovascular Disease - who.int

KDOQI Clinical Practice Guideline for Diabetes and CKD ...

★ ★ ★ ☆ ☆

The hazard ratios and 95% confidence intervals taken from the Northwick Park Heart Study, a prospective study of the risk of coronary heart disease (CHD), which has followed more than 3000 middle-aged men for over 6 years. For non-smokers all genotype groups have been pooled and the hazard ratio set at 1.

KDOQI Clinical Practice Guideline for Diabetes and CKD ...

Towards personalized cardiovascular prevention

★ ★ ★ ★ ★

Statins and New Onset Diabetes Mellitus Scott Coon, PharmD, BCPS, BCACP St. Louis College of Pharmacy St. Louis County Department of Public Health

Towards personalized cardiovascular prevention

Statins and New Onset Diabetes Mellitus

★ ★ ★ ★ ☆

Landmark Clinical Trials 1. www.lipid.org Learning Objectives ... – Main purpose of study, basis of power calculation – Results should be definitive ... WOSCOPS CARE LIPID AFCAPS/ TexCAPS NCEP ATP III Update 2004 HPS PROVE-IT ASCOT-LLA PROSPER ALLHAT-LLT …

Statins and New Onset Diabetes Mellitus

Landmark Clinical Trials - Lipid

★ ★ ☆ ☆ ☆

Risks, Benefits and Current Management Strategies of Statin Therapy Katherine Gambino, CRNP Erin Henry, CRNP Teri Miller, CRNP

Landmark Clinical Trials - Lipid

Risks, Benefits and Current Management Strategies of ...

★ ★ ★ ☆ ☆

trials (WOSCOPS, AFCAPS/TexCAPS, HS, CARE, LIPID, HPS) [1]. The beneficial effects of the HMG-CoA reductase inhibitors are usually attributed to their capacity to reduce the endogenous cholesterol synthesis, by competingly inhibiting the principal enzyme involved [2]. Since mevalonate, the product of HMG CoAreductase reaction, is the precursor not

Risks, Benefits and Current Management Strategies of ...

Statins: mechanism of action and effects

★ ★ ★ ☆ ☆

10/1/2003 · An unexpected outcome of the West of Scotland Coronary Prevention Study (WOSCOPS), a study of primary prevention with pravastatin, was a 30% reduction with pravastatin in the risk of developing diabetes during the study . Triglyceride-lowering or anti-inflammatory properties of pravastatin were postulated as a possible mechanism.

Statins: mechanism of action and effects

Secondary Prevention of Cardiovascular Events With Long ...

★ ★ ★ ☆ ☆

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that ...

Secondary Prevention of Cardiovascular Events With Long ...

Metabolic syndrome: pathophysiology, management, and ...

★ ★ ★ ☆ ☆

The lack of significance was attributed to the early termination of the study, which resulted in an insufficient number of events (930 achieved instead of the 1150 the study was powered for). Table 3.

Metabolic syndrome: pathophysiology, management, and ...

ASCOT: Anglo Scandinavian Cardiac Outcomes Trial - Medscape

★ ★ ★ ★ ★

5/30/2013 · The study enrolled 3966 participants to a heart healthy diet and 3866 participants to pravastatin 10 to 20 mg/day and diet (68% of the total study population were women). The primary endpoint for the study was first occurrence of CHD (nonfatal and fatal MI, sudden cardiac death, UA, coronary revascularization).

ASCOT: Anglo Scandinavian Cardiac Outcomes Trial - Medscape
Ca-ctel-exam-study.html,Caen-university-gmo-study-france.html,Cafe-bible-study-women.html,Cafes-to-study-sf.html,Cal-poly-slo-study-abroad.html